Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Share-based Compensation (2016 - 2026)

Conmed filings provide 17 years of Share-based Compensation readings, the most recent being $5.5 million for Q1 2026.

  • On a quarterly basis, Share-based Compensation fell 60.31% to $5.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $19.9 million, a 39.99% decrease, with the full-year FY2025 number at $28.3 million, up 10.55% from a year prior.
  • Share-based Compensation hit $5.5 million in Q1 2026 for Conmed, up from $4.9 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.9 million in Q1 2025 to a low of $4.5 million in Q1 2022.
  • Median Share-based Compensation over the past 5 years was $5.8 million (2022), compared with a mean of $6.2 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 122.16% in 2025 and later plummeted 60.31% in 2026.
  • Conmed's Share-based Compensation stood at $5.8 million in 2022, then increased by 2.88% to $5.9 million in 2023, then grew by 5.76% to $6.3 million in 2024, then dropped by 21.01% to $4.9 million in 2025, then increased by 11.2% to $5.5 million in 2026.
  • The last three reported values for Share-based Compensation were $5.5 million (Q1 2026), $4.9 million (Q4 2025), and $4.6 million (Q3 2025) per Business Quant data.